Infection Control Impact on Patient with Tuberculosis Chroretinitis in KSA Hospital Based Analysis
American Journal of Internal Medicine
Volume 7, Issue 3, May 2019, Pages: 77-80
Received: May 8, 2019;
Accepted: Jun. 14, 2019;
Published: Jun. 29, 2019
Views 559 Downloads 103
Mohammed Ahmed Garout, Community Medicine & Public Health, Umo Alqurah University, Faculty of Medicine, Makkah, KSA
Emad Algahdaly, Community Medicine & Public Health, Umo Alqurah University, Faculty of Medicine, Makkah, KSA
Magda Ramadan Abdultawab, Microbiology & Immunology & Infection Control, Faculty of Medicine, Ainshams University, Cairo, Egypt
Rana Mohammed Garout, Medical Student, IbnSina National Collage for Medical Studies, Jeddah, KSA
Raha Mohammed Garout, Medical Student, IbnSina National Collage for Medical Studies, Jeddah, KSA
Follow on us
Tuberculosis (TB) is an infectious disease responsible for significant morbidity and mortality worldwide. WHO estimates that one third of the world’s population is currently infected, with 9 million new cases occurring annually, leading to 3 million deaths per year, the disease affects the ocular anterior segment, the posterior segment, and adnexa. , The intraocular manifestations of TB include “mutton fat” keratic precipitates, posterior synechiae, vitreous snowballs, snow banking, retinal vasculitis, choroiditis, serpiginous-like choroiditis, and panuveitis] A definitive diagnosis of intraocular TB requires culture data, and direct demonstration of Mycobacterium tuberculosis in smears and via polymerase chain reaction (PCR) of intraocular fluid, The purpose of this study is to describe the ocular manifestations, diagnosis and treatment of tuberculosis and to emphasize the fact that ocular tuberculosis may occur in the absence of systemic clinical activity and may mimic several clinical entities The current study is an observational consecutive case series of patients diagnosed with intraocular tuberculosis managed at a hospital. Study the prevalence of ocular TB in cross section eye care center Magrabi hospital Jeddah, KSA, from June 1, 2013 to December 31, 2015. diagnosis of ocular TB is often presumed in the presence of suggestive ocular findings in combination with any of the following: Systemic findings consistent with TB infection, Positive interferon gamma release assay, Positive tuberculin skin test in asymptomatic individuals, Acid-fast bacilli (AFB) on direct smear or culture of MTB from ocular samples, Polymerase chain reaction (PCR), Fluorescein angiography (FA), RESULTS: 86 of 2542 patients for examination of retina in retina clinic were diagnosed as suspected tuberculosis chroretinitis, 20 percent of them had conformed diagnosed as TB. out Of 86, 24 (27.9%) had at least one episode of oculacomplaints, 7 patients were conformed with PCR. CONCLUSION: The diagnosis of presumed ocular tuberculosis remains a clinical challenge, although interferon-γ release assays they currently lack the specificity to distinguish between latent tuberculosis infection and active tuberculosis. molecular diagnostic PCR may be valuable in our ability to establish an earlier etiologic diagnosis and institute appropriate antimycobacterial therapy and ensure from implementation of infection control measurements.
Mycobacterium Tuberculosis, Choroidal Granuloma, Retinal Vasculitis, PCR, Acid-fast Bacilli (AFB)
To cite this article
Mohammed Ahmed Garout,
Magda Ramadan Abdultawab,
Rana Mohammed Garout,
Raha Mohammed Garout,
Infection Control Impact on Patient with Tuberculosis Chroretinitis in KSA Hospital Based Analysis, American Journal of Internal Medicine.
Vol. 7, No. 3,
2019, pp. 77-80.
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A Akal, T Goncu, FN Boyaci, ZHA Sak, F Yalcin, U Ozkan, and T Ulas: Primary Tubercular Chorioretinitis: Ann Med Health Sci Res. 2014 Nov-Dec; 4 (6): 965–967.
Centers for Disease Control and Prevention: Racial disparities in Tuberculosis-selected southeastern states. 2004. MMWR Morb Mortal Wkly; Rep 53: 556-9.
Sharma, B. Thapa, P. Lavaju: Ocular tuberculosis: an update, Nepal J Ophthalmol, 3 (5) (2011), pp. 52-67.
Gupta, V. Gupta: Tubercular posterior uveitis, Int Ophthalmol Clin, 2005, pp. 71-88.
Gonzalo G. Alvareza, Virginia R. Roth William Hodgeb: PlumX Metrics: Ocular tuberculosis: diagnostic and treatment challenges, 2009 Volume 13, Issue 4, Pages 432–435: https://doi.org/10.1016/j.ijid.2008.09.018.
Yeh S, Sen HN, Colyer M, Zapor M, Wroblewski K: Curr Opin Ophthalmol. 2012 Nov; 23 (6): 551-6. Update on ocular tuberculosis.
United States Center for Diseases Control (CDC) TB Treatment Guidelines: https://www.cdc.gov/tb/publications/guidelines/treatment.htm/2018.
Rao NA, Saraswathy S, Smith RE. Tuberculous uveitis: distribution of mycobacterium tuberculosis in the retinal pigment epithelium. Arch Ophthalmol. 2006; 124: 1777–1779. [PubMed] [Google Scholar].
Sanghvi C, Bell C, Woodhead M, Hardy C, Jones N. Presumed tuberculous uveitis: diagnosis, management, and outcome. Eye (Lond) 2011; 25: 475–480. [PMC free article] [PubMed] [Google Schola.
WHO. 2018 https://www.who.int/news-room/fact-sheets/detail/tuberculosis.
Olivier Van Der Meeren, M. D., Mark Hatherill, M. D., Videlis Nduba, M. B., Ch. B., M. P. H., Robert J. Wilkinson, F. Med. Sci., Monde Muyoyeta, M. B., Ch. B., Ph. D., Elana Van Brakel, M. B., Ch. B., Helen M. Ayles, M. B., B. S., Ph. D., German Henostroza, M. D: Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis, 2018. New England Journal of Medicine September 25, 2018, N Engl J Med 2018; 379: 1621-1634 DOI: 10.1056/NEJMoa1803484.
WHO: World Tuberculosis Day 2019. https://www.who.int/news-room/events/detail/2019/03/24/default-calendar/world-tb-day-2019.